UK detailed what it knows about the AstraZeneca vaccine and advised those under 30 not to use it

The Astrazeneca vaccine should not be offered to young people from 18 to 30 years old because it can have sequelae with its clots and must be replaced by other vaccines, such as Moderna or Pfizer, including your second dose if they have already received the first one. There is an immune problem that raises the platelets but they need to be study more the reasons for this process, which are unknown. It is not known whether it affects men or women more.

But this “correction of course” does not imply stopping vaccination neither in Great Britain nor in Europe because the benefits of the vaccine “are greater” than “the very rare side effects”, which produce a virus which can lead to death. One of the consequences of Covid is that it can produce un race in some cases.

This was the conclusion reached by the European Medicines Agency (EMA) in Amsterdam and shortly thereafter scientists from MHRA, the UK’s health and medical products regulatory agency, in a briefing special in London, on the Oxford vaccine – AstraZeneca.

This vaccine is boycotted by patients in Europe for fear of its side effects.

The alternative: Pfizer or Moderna

Britons aged 18 to 29 will be offered an alternative to the Oxford-AstraZeneca vaccine, after 79 people developed blood clots after inoculation, scientists from the British government have decided. They will suggest getting Pfizer or modern, depending on availability, and the vaccination site may be further from your home.

The UK Medicines and Health Products Regulatory Agency (MHRA) has concluded that there is “a possible link” between the Oxford vaccine and the “extremely rare and unlikely” blood clots with low platelets. Its origin is unknown.

Young people are much less likely to die from COVID-1. The Joint Committee on Vaccination and Immunization (JCVI) therefore decided that it was safer to recommend that you consider getting another vaccine. They don’t think they have supply problems in the kingdom because they already have Pfizer and Moderna arrived.

England’s Deputy Chief Medical Officer Professor Jonathan Van-Tam said the new advice on AstraZeneca is a “course correction” for the launch of the “very successful” vaccine in the UK. According to Van Tan, for most age groups, the “benefits outweigh the risks” of getting the vaccine.

He said the new advice on the Astrazeneca vaccine will haveto an insignificant impact when the vaccine was launched in the UK.

Symptoms to watch out for

“The recomendación está dando después of which a total of 79 personas en el Reino Unido han tenido coágulos de sangre tras su primera dosis de Oxford-AstraZeneca hasta el 31 de marzo”, declared the Dra. June Raine, executive director of the MHRA, What allowed the vaccine by AstraZeneca. A total of 51 women and 28 men were affected, including between 18 and 79 years old with these clots.

“The risk is four people in a million, ”added Dr. Raine.

He said anyone experiencing the following side effects four days after receiving a dose should see a doctor. They are: headaches.

• Bruises or spots beyond the vaccination site.

More than 5.6 million people in the UK are now fully vaccinated against COVID. JCVI said that “people of all ages who received the first dose of the Oxford vaccine they should continue to be offered the second dose ”, according to schedule.

JCVI President Prof. Wei Shen Lim said that “we recommend the preference of one vaccine over another. for a group age especially as a precaution and no serious safety concerns. He added that people at the start of 29 years old have to make a choice. But get vaccinated it’s much safer than not to receive it.

“British change of course”

British professor Van Tam said it is “quite common for doctors to change their preferences for drugs and vaccines”. He said the NHS will provide “the right vaccine at the right time. But some people” may have to travel further afield to be vaccinated.

He insisted that it remains “of vital importance” that people be vaccinated when asked to do so.

The UK is also currently injecting the Pfizer vaccine, with the first doses of the Moderna vaccine being delivered to Wales on Wednesday.

The Joint Committee’s decision on vaccination and immunization follows a review of the Oxford jab by the Medicines and Health Products Regulatory Agency.

Over the weekend, it was revealed that 30 people who received the vaccine in the UK had developed a blood clot, out of a total of 18.1 million who received it.

The MHRA has confirmed that seven of these people were dead Until March 24.

Prime Minister Boris Johnson said on Wednesday afternoon the government believed the Oxford / AstraZeneca vaccine to be “safe”.

During a visit to Cornwall, he insisted that “the crucial thing for everyone is to hear what the scientists, the medical experts have to say later today”.

What the Europeans say

From Amsterdam, the European Medicines Agency has launched its analysis of the Astrazeneca vaccine and its effects. British vaccine suffers a crisis of confidence in the EU, especially by the campaign from France and Germany suggesting it was not safe.

European medicines regulator said ‘unusual blood clots’ should be listed as a side effect “very rare” of the Oxford-AstraZeneca COVID vaccine.

The European Medicines Agency said it came to its conclusion after considering all available evidence.

European Union health ministers have been told the announcement would have an “immediate impact on vaccination plans” and “confidence in vaccines”.

The announcement came as British government advisers indicated that Britons between the ages of 18 and 29 will be offered an alternative to the Oxford-AstraZeneca vaccine when it becomes available.

Less risk, more benefit

The EMA reminded healthcare professionals and people receiving the vaccine to be aware of the possibility of “very rare cases of blood clots” associated with “low levels of platelets in the blood”, in two weeks post-vaccination.

He said that so far most of the reported cases have occurred women under 60.

The discovery of EMA follows a thorough examination of 86 cases of blood clots, including 18 fatalities, as of March 22, out of an estimated 25 million people who have received the vaccine.

However, despite the possible link, the regulator said the reported combination of blood clots and low blood platelets “is very rare.” The overall benefits of the vaccine for preventing COVID-19 “outweigh the risks of side effects.”

The Oxford vaccine is one of four vaccines authorized in the EU to protect against COVID-19.

The EMA says studies show it is effective in preventing coronavirus and also reduces the risk of hospitalization and death by COVID-19.

Restrictions on AstraZeneca

There have been concerns about whether the Oxford-AstraZeneca vaccine is suitable for younger age groups, following reports of rare blood clots on the continent. This has led several European countries to go back and forth in their own vaccination strategies in recent weeks.

But before the last EMA briefing, France, Germany and the Netherlands they had restricted Since then, the vaccine has been used by older people out of fear that younger recipients may have a higher potential risk of blood clots.

Earlier this week, the EMA’s head of vaccine strategy said it was “increasingly difficult” to say that there was “no cause and effect relationship” between the injection and “rare cases of unusual blood clots”.

The uncertainty regarding the dose of Oxford-AstraZeneca was presented as one of the main reasons for the slow vaccination schedule Europe, compared to the UK, where injection has been widely used alongside Pfizer. In vaccinations in France, there are hematologists, who check the platelet level of the future vaccinee in their analysis, to authorize the vaccine.

Paris, correspondent

ap